Effect of anti-S phase agents on human chromosomes
抗S期药物对人类染色体的影响
基本信息
- 批准号:8436839
- 负责人:
- 金额:$ 32.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-02-01 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:A549AddressAffectCell Adhesion MoleculesCell CycleCell LineCell LineageCell ProliferationCell surfaceCellsChIP-seqChromatinChromosomal BreaksChromosomal RearrangementChromosomal translocationChromosome FragilityChromosome StructuresCytarabineDNADNA biosynthesisDNA lesionDNA repair proteinDouble Strand Break RepairDoxorubicinDrug toxicityDrug usageFanconi&aposs AnemiaFetal HemoglobinFire - disastersGene ExpressionGene Expression ProfileGenesGenetic TranscriptionGenomeGenomicsH1299Hela CellsHematologic NeoplasmsHematological DiseaseHumanHuman ChromosomesKineticsKu70 proteinLeadLesionLocationMCF7 cellMalignant neoplasm of cervix uteriMalignant neoplasm of lungMediatingMessenger RNAMethodsNatureNeighborhoodsPathway interactionsPatternPharmaceutical PreparationsPolycythemia VeraPositioning AttributeProteinsPublishingRNA Polymerase IIRecruitment ActivityReplication OriginResearchS PhaseSecond Primary CancersSequence AnalysisSickle Cell AnemiaSiteTREX1 geneTechniquesTestingTime StudyTumor Suppressor Proteinsbasecancer therapycell typedensitydrug testingessential thrombocytopeniagemcitabinehydroxyureaimprovedinhibitor/antagonistmalignant breast neoplasmnext generation sequencingnovelpromoterpublic health relevancerepairedresponsetumor progression
项目摘要
DESCRIPTION (provided by applicant): Anti-S phase agents like doxorubicin, gemcitabine, cytarabine and hydroxyurea are in extensive use for the treatment of cancers and of hematological diseases such as essential thrombocytopenia, polycythemia vera and sickle cell anemia. All these agents are believed to cause replication fork stalling leading to activation of checkpoint pathways that inhibit cell proliferation. Yet, not much is known about how these inhibitors inhibit the origins of replication, of the sites/DNA lesions responsible for checkpoint activation and of the effect of these lesions on chromosome structure or gene expression. In addition, many of these agents are known to affect gene expression by unknown mechanisms. For example, hydroxyurea has been used in sickle cell anemia because it increases the expression of fetal hemoglobin and decreases the expression of cell-surface adhesion molecules. We have recently published genomic approaches to study time of replication, origins of replication and effects of anti-S phase agents on the replication origins in human cells We have discovered that two anti-S phase agents used for therapy lead to the firing of clustered neo-origins, leading to a high density of stalled replication forks at defined sites in the genome.
In this proposal we plan to determine whether this is a general feature of other anti-S phase agents, whether the sites where these clustered neo-origins occur are the same in different cell lines or whether the sites change when cells are exposed to these agents in all parts of the S phase. We will investigate whether the high density of stalled replication forks at clustered neo-origins make these sites of the genome susceptible to double-strand breaks (DSB) and chromosomal rearrangements. We will examine whether the disturbed state of the chromatin due to the high density of clustered neo-origins leads to suppression of gene expression. Finally, we will examine which, where and in what order checkpoint activators and DNA repair proteins are recruited to the stalled replication forks created by anti-S phase agents.
描述(由申请人提供):抗S期药物如阿霉素、吉西他滨、阿糖胞苷和羟基脲广泛用于治疗癌症和血液学疾病,如原发性血小板减少症、真性红细胞增多症和镰状细胞性贫血。所有这些试剂被认为引起复制叉停滞,导致抑制细胞增殖的检查点途径的激活。然而,关于这些抑制剂如何抑制复制起点、负责检查点激活的位点/DNA损伤以及这些损伤对染色体结构或基因表达的影响,知之甚少。此外,已知许多这些药剂通过未知机制影响基因表达。例如,羟基脲已被用于镰状细胞性贫血,因为它增加了胎儿血红蛋白的表达,降低了细胞表面粘附分子的表达。 我们最近发表了研究复制时间、复制起点和抗S期试剂对人类细胞中复制起点的影响的基因组方法。我们已经发现,用于治疗的两种抗S期试剂导致成簇的新起点的激发,导致基因组中限定位点处的高密度停滞复制叉。
在这项提案中,我们计划确定这是否是其他抗S期药物的一般特征,这些聚集的新起源发生的位点是否在不同的细胞系中相同,或者当细胞在S期的所有部分暴露于这些药物时,这些位点是否发生变化。我们将研究是否在聚集的新起源的高密度的停滞复制叉使这些网站的基因组易受双链断裂(DSB)和染色体重排。我们将研究由于成簇的新起源的高密度引起的染色质的干扰状态是否导致基因表达的抑制。最后,我们将研究哪些,在哪里和以什么顺序检查点激活剂和DNA修复蛋白被招募到停滞的复制叉创建的抗S期代理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anindya Dutta其他文献
Anindya Dutta的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anindya Dutta', 18)}}的其他基金
Involvement of Noncanonical Short RNAs in gene repression through the RNA-induced-silencing complex
非规范短 RNA 通过 RNA 诱导沉默复合物参与基因抑制
- 批准号:
10701797 - 财政年份:2022
- 资助金额:
$ 32.79万 - 项目类别:
Studies on ORC and double strand DNA break repair
ORC与双链DNA断裂修复的研究
- 批准号:
10377840 - 财政年份:2021
- 资助金额:
$ 32.79万 - 项目类别:
Studies on ORC and double strand DNA break repair
ORC与双链DNA断裂修复的研究
- 批准号:
10555198 - 财政年份:2021
- 资助金额:
$ 32.79万 - 项目类别:
Studies on ORC and double strand DNA break repair
ORC与双链DNA断裂修复的研究
- 批准号:
10328884 - 财政年份:2021
- 资助金额:
$ 32.79万 - 项目类别:
Mechanism of action of an lncRNA for directing muscle differentiation
lncRNA指导肌肉分化的作用机制
- 批准号:
10396900 - 财政年份:2016
- 资助金额:
$ 32.79万 - 项目类别:
Mechanism of action of an lncRNA for directing muscle differentiation
lncRNA指导肌肉分化的作用机制
- 批准号:
9914219 - 财政年份:2016
- 资助金额:
$ 32.79万 - 项目类别:
Effect of anti-S phase agents on human chromosomes
抗S期药物对人类染色体的影响
- 批准号:
8608500 - 财政年份:2013
- 资助金额:
$ 32.79万 - 项目类别:
Effect of anti-S phase agents on human chromosomes
抗S期药物对人类染色体的影响
- 批准号:
8997926 - 财政年份:2013
- 资助金额:
$ 32.79万 - 项目类别:
Androgen and MicroRNAs in Prostate Cancer
前列腺癌中的雄激素和 MicroRNA
- 批准号:
8038178 - 财政年份:2011
- 资助金额:
$ 32.79万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 32.79万 - 项目类别:
Research Grant